Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Montoya-Ferrer

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Emerging Infectious Diseases|August 2, 2011
Acute hepatitis C outbreak among HIV-infected men, Madrid, SpainAna Montoya-Ferrer, Daniel Seth Fierer, Beatriz Alvarez-Alvarez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 19, 2020
Clinical and Biological Factors Associated With Early Epstein-Barr Virus Infection in Human Immunodeficiency Virus-Exposed Uninfected Infants in Eastern UgandaAna Montoya-Ferrer, Armen Sanosyan, Alexis Fayd'herbe de Maudave, et al.
The Journal of Antimicrobial Chemotherapy|October 25, 2020
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimenRomain Palich, Clotilde Allavena, Gilles Peytavin, et al.
AIDS Research and Treatment|July 1, 2011
Tenofovir nephrotoxicity: 2011 updateBeatriz Fernandez-Fernandez, Ana Montoya-Ferrer, Ana B Sanz, et al.
Fundamental & Clinical Pharmacology|November 20, 2022
Chemsex in HIV pre-exposure prophylaxis users: Assessment of mood disorders and addictive behaviorHélène Peyriere, Jean-Marc Jacquet, Marianne Peries, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Emerging Infectious Diseases|August 2, 2011
Acute hepatitis C outbreak among HIV-infected men, Madrid, SpainAna Montoya-Ferrer, Daniel Seth Fierer, Beatriz Alvarez-Alvarez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 19, 2020
Clinical and Biological Factors Associated With Early Epstein-Barr Virus Infection in Human Immunodeficiency Virus-Exposed Uninfected Infants in Eastern UgandaAna Montoya-Ferrer, Armen Sanosyan, Alexis Fayd'herbe de Maudave, et al.
The Journal of Antimicrobial Chemotherapy|October 25, 2020
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimenRomain Palich, Clotilde Allavena, Gilles Peytavin, et al.
AIDS Research and Treatment|July 1, 2011
Tenofovir nephrotoxicity: 2011 updateBeatriz Fernandez-Fernandez, Ana Montoya-Ferrer, Ana B Sanz, et al.
Fundamental & Clinical Pharmacology|November 20, 2022
Chemsex in HIV pre-exposure prophylaxis users: Assessment of mood disorders and addictive behaviorHélène Peyriere, Jean-Marc Jacquet, Marianne Peries, et al.
Pageof 1